Objectives: Magnesium has protective effects in ischaemiareperfusion injury, and is involved in immunomodulation. We investigated the effects of magnesium pretreatment on the secretion of T helper (Th) cytokines and on the severity of post-reperfusion syndrome (PRS) in patients undergoing living donor liver transplantation (LDLT). Methods: forty patients were allocated to two groups of 20 (magnesium and saline groups). Blood samples for cytokine analysis were collected before infusion of the study solution at the end of anhepatic phase (time point 1), as well as five min and 30 min after allograft reperfusion (time points 2 and 3, respectively). Levels of cytokines were quantified using a sandwich enzyme immunoassay test kit. Results: The duration of PRS was shorter in the magnesium group (p = 0.038). The level of interferon (IFN)-␥ released from Th1 was lower in the magnesium group at time point 3 (p = 0.009). Of the cytokines released from Th2 cells, interleukin (IL)-6 was present in higher concentrations in the magnesium group at time points 2 and 3 (p<0.05). The concentrations of IL-4 and IL-10, which were secreted from Th2 cells, were also higher in the magnesium group at time point 3 (p<0.05). The IFN-␥ /IL-6, IFN-␥ /IL-4 and IFN-␥ /IL-10 ratios were lower in the magnesium group after allograft reperfusion. Conclusions: Magnesium pretreatment attenuated PRS and reinforced Th2 cell activity, shifting the Th1-to-Th2 cytokine balance towards Th2 in patients undergoing LDLT.
Liver transplantation (LT) is associated with a complex sequence of events such as haemodynamic disturbance, immune reaction, and reperfusion injury. Hepatic ischaemia-reperfusion (IR) injury, which occurs after hepatic vascular declamping and reperfusion of the grafted liver, is always a subject of interest. IR injury is thought to be a result of increased oxygen-derived free radical release and is characterised by the release of inflammatory mediators, including cytokines, which may then cause graft damage and rejection [1] [2] [3] [4] .
IR injury also occurs in other clinical situations, such as myocardial infarction, ischaemic spinal cord injury and stroke. Many strategies have been used in an attempt to reduce or prevent IR injury, including surgical interventions, the use of pharmacological agents and gene therapy; however, few treatments are currently available [5, 6] . Several experiments have demonstrated protective effects of magnesium in animal models of IR injury [7] [8] [9] . Magnesium treatment before reperfusion of grafted liver during LT reduces levels of serum lactate [10] . Intravenous administration of magnesium during coronary occlusion causes a significant reduction in the extent of myocardial infarcts [7, 11] . Magnesium enhances electrophysiological and neurobehavioral recovery, and reduces brain infarction after cerebral IR [8] . In addition, it has protective effects on reperfusion injuries of the spinal cord in rabbits [9] . This is because magnesium provides cellular protection during ischaemia and reperfusion by stabilising the cellular transmembrane potential, suppressing excessive calcium influx and reducing cellular energy demand [12] . Recent studies have revealed that magnesium is associated with inflammation. Low magnesium promotes the activation of transcription factor activator protein-1 and nuclear factor-Kappa B, and magnesium supplementation prevents the activation of the transcription factors [13, 14] . Furthermore, several investigations have focused on the immunomodulatory effects of magnesium. These studies have revealed that magnesium reduces cytokine production and has broad anti-inflammatory activity [15, 16] .
Thus, the immunomodulatory action of magnesium, combined with its cellular protection and membrane stabilising effects, may help reduce IR injury and/or post-reperfusion syndrome (PRS) in patients undergoing living donor liver transplantation (LDLT). However, little is known regarding the effects of magnesium on hepatic IR injury considering the immunological response during LT. In the present study, we investigated the effects of intravenous magnesium pretreatment on levels of T helper (Th) cytokines and their ratio at allograft reperfusion, and evaluated the beneficial effects of magnesium pretreatment on the severity of PRS.
Methods and materials
The present prospective study was conducted in 45 patients undergoing LDLT between January 2011 and March 2012 at Seoul St. Mary's Hospital, Seoul, Korea after receiving approval from the Institutional Review Board (KC10EISI0623). Written informed consent was obtained from all patients before enrolment. Patients with unstable preoperative cardiovascular status, severe hypoxaemia due to acute respiratory distress syndrome, hepatopulmonary syndrome, evidence of infection other than vital hepatitis or autoimmune disease, and minors less than 18 years old were excluded. Patients were randomly allocated to either a saline or magnesium group using random, computer-generated numbers.
Each patient was induced with general anaesthesia using 4-5 mg/kg b.wt. thiopental sodium and 1 mg/kg b.wt. succinylcholine without premedication, and was then intubated. General anaesthesia was maintained with sevoflurane and medical air in oxygen (FiO 2 ; 0.4). Neuromuscular block was facilitated by a bolus dose of 0.25 mg/kg b.wt. atracurium followed by infusion of 6 g/kg b.wt. /min atracurium continuously to maintain adequate relaxation for the operation. Mechanical ventilation was controlled with a tidal volume of 10 mL/kg b.wt., and the respiratory rate was adjusted to obtain an end-tidal partial pressure of CO 2 between 35 and 40 mmHg.
Immediately after the induction of anaesthesia, a 22-gauge angiocatheter was inserted into the right radial artery for continuous monitoring of blood pressure and analysis of arterial blood gas. A 9-Fr. multi-lumen introducer (MAC TM ; Arrow International Inc., Reading, PA, USA) was inserted into the right internal jugular vein, and a Swan-Ganz catheter (Arrow International) was inserted via the introducer to monitor and measure haemodynamic variables. A two-lumen catheter (Arrow International) was inserted via the right subclavian vein to administer drugs.
Right-lobe LDLT using the piggyback technique was performed by two operators: portal vein anastomosis followed by hepatic artery anastomosis and bile duct reconstruction. All liver allografts were prepared with histidinetryptophan-ketoglutarate solution (Custodiol ® ; Dr Franz Köhler Chemie GmbH, Bensheim, Germany). No patient received a veno-veno bypass or temporary portocaval anastomoses. LT was always performed by the same team of surgeons and anaesthesiologists, using the same surgical and anaesthetic techniques.
Twenty minutes before the beginning of the neohepatic phase, the patients received either 35 magnesium sulphate injection; Daihan Pharma Co. Ltd., Seoul, Korea) mixed with 50 mL normal saline (magnesium group, n = 20) or an equivalent volume of normal saline (saline group, n = 20) over 20 min. An anaesthesiologist not involved in the management of patient anaesthesia prepared the covered syringe pump for the magnesium solution and saline, and held the randomisation code until the end of the study. Other anaesthesiologists, who were not involved in preand post-operative patient evaluation and were blinded to the group assignment, administered the anaesthesia. The patients, surgeons, and anaesthesiologists in charge were blinded to the group assignments for the duration of the study.
The blood samples for magnesium, and cytokine analysis were taken from the radial artery at the following time points: before administration of the study solution at 20 min before the start of neohepatic phase, which was considered the baseline value (time point 1), as well as five min and 30 min after allograft reperfusion (time points 2 and 3, respectively). For the magnesium assays, the photometric xylidyl blue (Sekisui Chemical Co., Ltd., Osaka, Japan) method was used with a Hitachi 7600 Automatic analyser (Hitachi High Technologies Co., Tokyo, Japan). For cytokine immunoassays, the blood samples collected were transferred to test tubes (BD Vacutainer; cat. REF 367896) , and sent to the laboratory in an ice-filled container. After centrifugation at 1,500 rpm for 10 min at 4
• C, the serum was carefully collected and kept frozen at −70
• C. The cytokines were quantified by a sandwich enzyme-linked immunoassay (ELISA) using a quantitative sandwich enzyme immunoassay test kit with specific first and second antibody pairs and recombinant proteins (Quantikine ® ; R&D Systems, Inc., Minneapolis, MN, USA). ELISA was performed by overnight incubation of the first antibodies in 96-well ELISA plates, followed by washing and addition of blocking buffer for 2hr at room temperature. Thereafter, samples of recombinant cytokine (concentrations of 200 ng/mL) were added. After a 2-h incubation at room temperature, plates were washed and extra-avidin-alkaline phosphatase conjugate (SIGMA Chemical Co., St. Louis, MO, USA) diluted to 1:2000 was added for 2 h at room temperature. After washing, the substrate solution (phosphate disodium salt hexahydrate) dissolved in diethanolamine was added for 30 min and the reaction was stopped by adding 0.2N NaOH solution. The optical density was read using a microplate reader (VersaMax ®, Molecular Device, Sunnyvale, CA, USA) at 450 nm. Tumour necrosis factor (TNF)-␣ and interferon (IFN)-␥ were quantified as the cytokines for Th1, and interleukin (IL)-4, IL-6, and IL-10 were quantified as the cytokines for Th2. Each blood sample was analysed twice, and the average value was applied for the analysis. The ratio of Th1-to-Th2 was subsequently calculated.
Intravenous fluids, vasopressors, and inotropes were administered while monitoring haemodynamics and clinical parameters to maintain a central venous pressure of 8−10 cmH 2 O, mean blood pressure >65 mmHg, pulmonary artery wedge pressure 10−14 mmHg, and urine output 0.5−1 mL/kg b. wt. /h. Intravenous fluids included hydroxyethyl starch (6%; 130/0.4) solution (Voluven; Fresinius Kabi, Bad Homburg, Germany), and 20% albumin as colloids. Sodium chloride (0.45%) and Normosol-R (pH 7.4; plasma solution A injection; CJ Pharma, Eumseong-gun, South Korea) were used as crystalloid solutions. Packed red cells (PRCs) were transfused to maintain a target haematocrit of 30%. Platelet concentrate, fresh frozen plasma (FFP), and cryoprecipitate were administered under the guidance of thromboelastography (TEG; Thromboelastograph Analyzer 5000; Haemoscope Corp., Niles, IL, USA) and laboratory-based coagulation profiles. Five units of platelet concentrate were transfused when the maximum amplitude of the TEG was <45 mm (normal range, 48-60 mm), and the platelet count was <40,000/L [17] . If bleeding persisted, two units of FFP were administered when the reaction time of TEG was >30 mm (normal range, 19-28 mm), and the prothrombin time as the international normalized ratio was >2.0. Five units of cryoprecipitate were administered when the ␣-angle of the TEG was <30
• (normal range, 29-43
• ), and the fibrinogen level was <100 mg/dL, with persistent bleeding despite administration of platelet concentrate and FFP. Tranexamic acid was administered using a loading dose of 10 mg/kg b.wt., followed by infusion at 1 mg/kg b.wt. /h during the rest of the operation when the percentage reduction in maximum amplitude after 60 min was >15% (normal range, <15%) [18] . Severe metabolic acidosis was corrected with sodium bicarbonate when the pH was <7.2 and the base deficit was >10 mEq. The amount of sodium bicarbonate administered was calculated as follows: A low ionised calcium level (<0.9 mmol/L) was corrected with calcium chloride. Before neohepatic reperfusion, 125 mg prednisolone was injected as the immunosuppressive regimen in all patients. When the liver allograft was reperfused, the incidence and severity of PRS were compared between groups. PRS was defined as a >30% decline in the mean arterial pressure lasting longer than 1 min and occurring within 5 min of graft reperfusion [19] . When necessary, epinephrine was administered in an incremental bolus of 10-50 g to maintain haemodynamic stability.
Based on our preliminary study, the expected between-group difference in the mean IFN-␥ immediately after allograft reperfusion was 32.1 pg/mL with a standard deviation (SD) of 35.5. Based on [( -)/␦] = 0.9 (where -is the difference in mean and ␦ = SD), 20 patients per group were adequate to achieve a power of 80% with an alpha error of 0.05.
Data are presented as means ± SD, medians with quartile values, or absolute values (proportions). According to the result of the verification of normal distribution by the Shapiro-Wilk test, Student's t-test or the Mann-Whitney U-test for continuous variables and chi-squared test or Fisher's exact test for categorical variables were performed to compare the demographic and laboratory data. The Wilcoxon rank-sum test was used to compare cytokine concentrations between groups at the time points. The Friedman test was performed to compare cytokine concentrations among the time points within the group, and Duncan's post-hoc test was used if statistical significance was noted. All tests were two-sided, and p<0.05 was deemed to be statistically significant. The SPSS ® statistical package, version 18.0 (SPSS Inc., Chicago, IL, USA) was used for the statistical analyses.
Results
In total, 45 patients were recruited for the study. Five patients were excluded based on the exclusion criteria ( figure 1) . The characteristics of patients are summarised in table 1. No difference was found in demographic data, including the model for end-stage liver disease (MELD) score and causes of liver cirrhosis between groups. Pre-operative laboratory findings were not different between groups except for the concentration of serum creatinine and the value of base excess. The serum creatinine level was higher in the saline group than in the magnesium group; however, the concentration was within the normal range in both groups (table 2).
The incidence of PRS and the duration of hypotension at reperfusion were significantly lower in the magnesium group than in the saline group (p = 0.047 and p = 0.038, respectively). Haemodynamic values including cardiac index (CI), heart rate, and mean arterial pressure (MAP) were comparable at time point 1 between groups; however, CI and MAP showed higher values at time point 2 in the magnesium group (p = 0.018 and p = 0.058, respectively) (table 2).
The serum magnesium concentration was not different at time point 1; however, it was significantly higher in the magnesium group at time points 2 and 3, although the concentration of magnesium was within the normal range (table 2).
No significant difference was found in baseline (time point 1) cytokine concentrations, before the study solution infusion, between the two groups. The IFN-␥ level was significantly lower in the magnesium group than in the saline group at time point 3 (p = 0.009); however, the TNF-␣ level was not different between groups ( figure 2A) . Of the Th2 cytokines, the IL-6 concentration was significantly higher in the magnesium group than in the saline group at time points 2 and 3 (p = 0.008 and p = 0.001, respectively). The IL-4 and IL-10 levels were also significantly higher in the magnesium group than in the saline group at time point 3 (p = 0.030 and p = 0.010, respectively) (figure 2B). The baseline (time point 1) ratio of IFN-␥, a Th1 cytokine, to IL-6, a Th2 cytokine, was not different between groups. The IFN-␥/ IL-6 ratio decreased at time points 2 and 3 in the magnesium group and was significantly lower than that in the saline group (p<0.001, both). The IFN-␥/IL-4 and IFN-␥/IL-10 ratios showed decreased values at time point 3 in the magnesium group, revealing similar patterns ( figure 2C ).
Discussion
IR injury is induced not only by toxic responses to oxygen-derived free radicals but also by immune responses, including the release of inflammatory mediators such as cytokines [20] . the survival of allografts in patients undergoing LT [21] [22] [23] [24] [25] . Thus, the suppression of harmful cytokine responses related to IR injury by inducing immunomodulation is an important approach for improving patient outcome. In the present study, when magnesium was administered to patients undergoing LDLT immediately before allograft reperfusion, the post-reperfusion concentration of IFN-␥, a Th1 cytokine, was significantly lower than the respective concentration in the saline group. Conversely, the post-reperfusion concentrations of IL-4, IL-6, and IL-10, which are Th2 cytokines, were significantly higher in the magnesium group than in the saline group. This suggests that magnesium pretreatment shifted the Th1-to-Th2 balance towards Th2 and thus plays an immunomodulatory role after allograft reperfusion.
Th cells are initially capable of producing many cytokines and are prompted into a more restricted and focused pattern of cytokine production depending on signals received during the stress state [26] . Thus, Th cells can be classified according to the pattern of cytokines they produce. Th1 cells secrete IFN-␥ which activates cytotoxic T lymphocytes and macrophages. Th1 cells promote protective cell-mediated immune responses that may result in fewer postoperative infections. Alternatively, Th2 cells, which produce IL-4, IL-6, and IL-10, drive B cells to differentiate and produce immunoglobulins, and are associated with humoral or antibody-mediated immunity [26, 27] . Therefore, polarisation of Th cells toward either Th1 or Th2 can significantly influence subsequent immune responses. Th2 lymphocytes also play a crucial role in the regulation of the cytokine balance, providing an equilibrium between pro-and anti-inflammatory cytokines, as Th2 lymphocytes produce IL-4 and IL-10, which are anti-inflammatory cytokines [28] . In the present study, magnesium pretreatment induced increased release of IL-4 and IL-10 after reperfusion, contributing to the maintenance of the cytokine balance.
Interestingly, our results showed that magnesium treatment increased secretion of IL-6, which (10) 18 ( is a pro-inflammatory cytokine. According to previous reports, the association between magnesium supplementation and the level of IL-6 is controversial. Some studies have suggested that a low magnesium level increases the levels of IL-6 [29] ; on the other hand, others have indicated that a low magnesium level decreases levels of mRNA for IL-6 in alveolar macrophages [30] . Thus, IL-6 is regarded as a pleotropic cytokine; the effects of magnesium administration on IL-6 levels need to be verified and elucidated. Although IL-6 is widely considered to induce excessive inflammatory responses as a pro-inflammatory cytokine, it plays an important role in the initiation and maintenance of liver regeneration [31] [32] [33] . The concentration of IL-6 was also closely related to postoperative prognosis in an animal study [34] . Therefore, when interpreting the results of our study, the consequence of increased concentrations of IL-6 after reperfusion should not be limited to its pro-inflammatory action.
Regarding PRS, we found that magnesium pretreatment decreased the incidence of PRS, and it was associated with attenuated PRS, implying that magnesium helps to reduce hepatic IR injury. The importance of the shortening of the duration of PRS by as much as 30% [(166-113)/166 × 100] or about 1 min (166 s in the saline group versus 113 s in the magnesium group) should not be underestimated, considering that the extreme haemodynamic instability immediately after reperfusion is a great threat to the patients.
The mechanism of this beneficial effects of magnesium pretreatment on PRS and immunomodulation is unclear; however, several possibilities exist. From a clinical perspective, a shorter duration of PRS in the magnesium group can be attributed to the cardiovascular stabilising effect of magnesium [35] . Moreover, patients with end-stage liver disease usually have hypomagnesaemia because of decreased intake and impaired 51 † p<0.05 between the two groups over time. T1, before infusion of the study solution at 20 min before the start of the neohepatic phase. T2, 5 min after reperfusion. T3, 30 min after reperfusion. free radical production in endothelial cells and circulating white blood cells [29, 38] . Conversely, normomagnesaemia has a protective role against harmful inflammatory reactions [16, 39] . Thus, it is reasonable to assume that correction of hypomagnesaemia before reperfusion in the present study may have resulted in the increased production of anti-inflammatory cytokines by Th2 lymphocytes.
The over-normalisation of serum magnesium levels must be avoided. Hypermagnesaemia can cause peripheral vasodilation, leading to worsening of hypotension at reperfusion of allografts. In addition, magnesium is a powerful cerebral vasodilator that leads to deleterious situations in patients with hepatic encephalopathy [36] . Therefore, it is important to determine carefully the dose of magnesium that is to be administered. Based on previous studies, magnesium is usually administered at 1.5-2 g intravenously over 30 min to correct hypomagnesaemia [12, 40] . We selected a dose of 35 mg/kg b.wt. of magnesium sulphate, which is the equivalent of 1.5-2 g magnesium for patients of 60-70 kg. The level of magnesium in the serum was within the normal range without inducing hypermagnesaemia in the magnesium group. Thus, the magnesium dose applied in our study was considered to be appropriate.
In conclusion, in patients undergoing LDLT, magnesium pretreatment immediately before allograft reperfusion attenuated PRS, and led to a favourable cytokine balance by immunomodulation of Th2 cytokines.
